Weight loss drug Zepbound approved to treat sleep apnea
Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.
More Stories
Popular injectable weight loss drug Zepbound has become the first prescription drug that can be taken to treat obstructive sleep apnea.
It has been approved by the FDA specifically for people who are considered obese and have moderate to severe obstructive sleep apnea.
Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.
Study participants experienced nearly 25 fewer breathing disruptions per hour compared to those on a placebo.
Researchers say with weight loss, people reduce fat tissue inside their neck and throat, which can help keep airways open and make it easier to breathe while they sleep.
Doctors say sleep apnea can cause so many little wake ups during the night, some people who have it may not realize they're sleep-deprived.
If untreated, sleep apnea can lead to an increased risk of diabetes, dementia, stroke and heart problems, according to doctors. Sleep apnea can also impact a person's heart, brain and metabolism.
To find a sleep medicine center near you, click here.
